Kornimate/medical-research-clean huggingface dataset:
a study of ly3200882 in participants with solid tumors

Conditions: Solid Tumor

Summary: the main purpose of this study is to evaluate the safety of the study drug known as ly3200882 in participants with solid tumors.


Eligibility criteria:
inclusion criteria: * the participant must have histological or cytological evidence of cancer. * have adequate organ function. * have eastern cooperative oncology group (ecog) scale performance status of 0 or 1. * are able to swallow capsules and tablets. exclusion criteria: * have moderate or severe cardiovascular disease. * have a serious concomitant systemic disorder. * have acute leukemia.

Keywords: tgf beta
non-interventional study of cabozantinib in adults with advanced renal cell carcinoma

Conditions: Renal Cell Carcinoma

Summary: the objective of this study is to understand the utilization of cabozantinib in subjects with advanced renal cell carcinoma (rcc) following prior vegf-targeted therapy in real life settings in terms of dose modifications due to adverse events (aes) when used as a second line therapy or third and later line therapy. other patterns of use of cabozantinib will also be described.

the study will follow the real-life management of patients in clinical practice. visits will take place according to the study site's clinical practice. cabozantinib is to be administered as directed by the investigator according to the study site's usual clinical practice and the cabometyx™ summary of product characteristics (smpc).

Eligibility criteria:
inclusion criteria: * age ≥18 years old * has a diagnosis of advanced rcc * has received at least one prior vegf-targeted therapy * for whom the treating physician has decided to start treatment with cabozantinib tablets prior to inclusion * no previous exposure to cabozantinib prior to inclusion * not concurrently involved in an interventional study * consents to participate in this noninterventional study exclusion criteria: * there are no exclusion criteria for this study.
the efficacy and safety of thunderbeat in thyroid surgery

Conditions: Thyroid

Summary: the aim of this study is to compare the results of total thyroidectomy using the thunderbeat device to that with the harmonic scalpel.

thunderbeat instrument combines an advanced bipolar clamp to the existing ultrasonic cutter. in the animal study with pig, the result of thunderbeat shows fast abalation rate and same thermal conductivity. there has been reported a significant reduction in operative time and same complications with thunderbeat in gynecology patient who underwent laparoscopic hysterectomy with lymph node dissection. comparison of the utilization of this new device, however, with the harmonic scalpel in thyroidectomy has not been performed in any study. the objective of this study is to compare the results of thyroidectomy using the thunderbeat to that with the harmonic scalpel device in respect to hemostasis, operative time and perioperative complications. all patients undergoing a thyroidectomy in our endocrine surgery department are randomized into those operated with thunderbeat (group a) and those with harmonic scalpel (group b).

Eligibility criteria:
inclusion criteria: * thyroidectomy * normal vocal cord exclusion criteria: * additional surgical procedures together with the total thyroidectomy (i.e., parathyroidectomy or cervical lymph node dissection) * thyroid cancer patients with lymph node metastasis * pregnant women * uncontrolled hypertension, dm, chronic kidney failure, coagulation disorders * aspirin or anti-platelet agent in 7 days * graves' disease or hashimoto thyroiditis * history of radiation treatment in head and neck area

Keywords: thyroidectomy thunderbeat
detection of ctc and ctdna in the diagnosis of metastasis in gastric cancer

Conditions: Stomach Neoplasms; Metastasis

Summary: to investigate the value of ctcs and ctdna in the diagnosis of metastasis in ascites/peritoneal flushing fluid and blood; to investigate the influence of laparoscopic co2 pneumoperitoneum establishment on peritoneal and hematogenous metastasis of advanced gastric cancer; to explore the influence of the number and type of ctcs and ctdna on metastasis and prognosis.


Eligibility criteria:
inclusion criteria: 1. patients who sign informed consent. 2. gastric cancer is determined by more than 2 pathologists. 3. patients with borrmann iii/iv gastric cancer. exclusion criteria: 1. patients who complicate with other malignant tumors. 2. patients who complicate with other serious heart and lung diseases. 3. patients who receive preoperative neoadjuvant chemotherapy.

Keywords: diagnosis
efficacy and safety of xg-102 in reduction of post-cataract surgery intraocular inflammation

Conditions: Inflammation; Pain; Cataract

Summary: the purpose of this study is to evaluate the clinical efficacy and safety of xg-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.


Eligibility criteria:
key inclusion criteria: * have provided written informed consent, approved by the appropriate institutional review board; * be greater than or equal to 18 years of age of either sex or any race; * be planning to undergo unilateral cataract extraction via phacoemulsification and posterior chamber intraocular lens (pciol) implantation in the study eye; * have a pin-hole visual acuity (va) \< 1.0 logarithm of the minimum angle of resolution (logmar) in the operative eye and fellow eye as measured using an early treatment for diabetic retinopathy study (etdrs) chart at visit 1; * (for females of childbearing potential) agree to have urine pregnancy testing performed at visit 1 (must be negative) and at exit visit; must not be lactating; and must agree to use a medically acceptable form of birth control1 throughout the study duration. women of childbearing potential include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy). key exclusion criteria: * have a known sensitivity or allergy to the class of medication of the active ingredient in the study medication or any of the study medication's components; * have any intraocular inflammation (e.g., white blood cells or flare) present in the study eye at the visit 1slit lamp examination; * have a score greater than "0" on the ocular pain assessment at visit 1 or 2 in the study eye; * have an immunosuppressive or an autoimmune disease that in the opinion of the investigator could affect intraocular inflammation or the normal healing process of the eye; * have active or chronic/recurrent ocular or systemic disease that is uncontrolled and will likely affect wound healing; * currently have suspected or known malignancy or be currently receiving antineoplastic therapy; * be a female who is currently pregnant, planning a pregnancy, lactating, not using a medically acceptable form of birth control throughout the study duration, or have a positive urine pregnancy test at visit 1; * use anti-inflammatory agents, analgesics/pain relievers (including opioids, narcotics and other pain medications) or immunomodulating agents, systemically, or in either eye, and/or use medications for benign prostatic hyperplasia (bph), from the washout period through the duration of the study
tarsal tunnel syndrome and fibromyalgia

Conditions: Tarsal Tunnel Syndrome

Summary: widespread pain is observed in patients diagnosed with fibromyalgia, and lower extremity and foot pain are also common. in our study, we aimed to evaluate the relationship between foot pain and tarsal tunnel syndrome in female patients diagnosed with fibromyalgia.


Eligibility criteria:
inclusion criteria: * 18-65 age * diagnosed with fibromyalgia according to acr criteria exclusion criteria: * have any severe mental or psychological disorder * have significant hearing and/or vision loss * presence of foot deformity, previous fracture, arthritis, tendon pathology that may cause foot pain detected in the physical examination of the foot and ankle joint. * presence of systemic inflammatory disease * having any systemic disease that may cause polyneuropathy.

Keywords: tarsal tunnel syndrome, fibromyalgia, neuropathic pain, emg
do your genes put you at a higher risk of developing mesothelioma

Conditions: Mesothelioma

Summary: the purpose of this research study is to investigate the possibility that a person's genes put a person at a higher risk of developing mesothelioma. the investigators will examine genes from dna (genetic material) isolated from blood. this study will also examine the impact of environmental and work exposures and family history of common cancers on the development of mesothelioma. the genetic markers in this study will basically identify how a person's body processes frequently encountered environmental pollutants and will not tell about chromosomes, specific diseases, or other potential health problems.

mesothelioma is a cancer that develops from serosal surfaces usually in response to prior asbestos exposure. a history of asbestos exposure can be elicited in more than 80% of mesothelioma victims. however, asbestos exposure alone is not sufficient to cause the development of mesothelioma. nearly 27 million individuals in the us, were exposed to asbestos in the work place between 1940 and 1979 but just 3,000 new cases of mesothelioma are diagnosed each year. therefore, the investigators hypothesis is that genetic variation in addition to asbestos exposure, and host factors contribute to the development of mesothelioma. it is estimated, based on the investigators preliminary studies, that a population in excess of 1,000 subjects with mesothelioma is required to perform a valid gwas. therefore a multicenter approach is necessary to collect data and dna on sufficient numbers with mesothelioma to adequately evaluate genetic risk. it is the aim of this proposal to develop a consortium of mesothelioma investigators to share phenotypic data and dna samples and to perform genome wide association scanning (gwas).

Eligibility criteria:
inclusion criteria: * subjects able to provide informed consent who suffer from mesothelioma exclusion criteria: * inability to provide informed consent * absence of mesothelioma in self

Keywords: genetics of mesothelioma mesothelioma consortium gwas asbestos
lap-band observational cohort

Conditions: Epworth Sleepiness Scale; Glycemic Control; Liver Function; Inflammation; Iron and Bone Turnover; SF-36; IW-QOL Lite HRQoL

Summary: to prospectively observe the association of the lap-band procedure on quality of life, anthropometric, metabolic and biochemical parameters in morbidly obese patients when performed by experienced us surgeons. the study will also include a complete economic analysis of the lap-band procedure and follow-up costs hypothesis: measurements defining quality of life and the severity of obesity and obesity related comorbidities improve significantly over baseline with the lap-band system treatment at 6 and 12 months post surgery when performed by an experienced surgeon.

study type: observational cohort. single arm (non-comparative), non-randomized, multi-site surgical case series. objective: to prospectively observe the association of the lap-band system device on measurements of quality of life, anthropometric, metabolic and biochemical parameters in morbidly obese patients when performed by experienced u.s. surgeons. cost effectiveness analysis will also be done. numbers: this study will enroll 240 patients total from six u.s. bariatric surgical practices duration: individual subject participation will be approximately 15 months. data will be collected at a baseline less than three months prior to surgery or before starting a very low calorie diet (vlcd), then at 6 and 12 months post surgery. the total duration, including enrollment, of the observational period for the cohort is expected to be 21 months. subjects have the option to consent for future contact by investigators for a period of 10 years following their surgery.

Eligibility criteria:
inclusion criteria: * morbid obesity: bmi \>40 kg/m2 or * bmi \> or equal to 35 kg/m2 with significant obesity related comorbidity * age 18 years old or older * dietary attempts at weight control have been ineffective * consented for surgery with lap-band system by pre qualified bariatric surgeon * willingness and ability to follow protocol requirements * residing within a reasonable distance from the surgeon's office and being able to travel to the surgeon's office to complete all routine follow-up visits exclusion criteria: * previous bariatric surgery * psychological impairments that would impede compliance with study follow up schedule, as determined by attending surgeons

Keywords: health outcome study
the roles of vitamin d and microbiome in children with post-acute covid-19 syndromes (pacs) and long covid

Conditions: Post-acute COVID-19 Syndromes

Summary: a double-blind study to evaluate the role of human microbiome and vitamin d in the development of long covid and pacs in children.

children worldwide are at risk of sars-cov-2 infection because of a lack of approved vaccines for children aged 0-4 years. moreover, sars-cov-2 infected children also suffered with long term sequels of virus infection, which involved multiple organs, such as fatigue, post-exercise malaise, skeletal muscular pains, headache, palpitation and insomnia. in fact, there is limited evidence available on the long-term impact of sars-cov-2 infection in children. recent studies have shown critical-ill covid-19 patients suffered with low vitamin d concentration and microbiome dysbiosis in their respiratory and gastrointestinal system. vitamin d has been known to counteract several respiratory virus infections as well as beneficial functions in multiple organs. also, commensal microbiota in lung and intestinal tracts exert protective functions against virus infections and, through its metabolite and axis links, has anti-inflammatory actions and homeostasis in multiple organs. hence, in this study, the investigators hypothesis that long covid or post-acute covid syndrome (pacs) in children is due to the effect of post-virus infection on the immuno-metabolism change (vitamin d deficiency) and perturbation of gut microbiota (microbiome dysbiosis), therefore our study aims are first, make the comparisons of vitamin d levels and respiratory and gut microbiome between symptomatic and non-symptomatic post-covid children using cross-sectional study. next, for interventional study, patients will be divided in two groups to receive supplementation of vitamin d or placebo for 6 months to evaluate the effect of vitamin d on the symptoms relieve and improvement of microbiome dysbiosis in post-acute covid syndrome (pacs) children. the investigators expect through this study, the investigators can learn more on the pathogenesis and the effect of vitamin d and microbiota in long covid and pacs in children.

Eligibility criteria:
inclusion criteria: 1. children aged 0-18 years 2. the child sought/needed primary or secondary medical care for covid-19 3. laboratory (rt-pcr, covid-19 antigen tests or sars-cov-2 antibody testing) or physician confirmed sars-cov-2 infection based on classic clinical symptoms and/or ground-glass opacification on ct imaging. 4. 28 days - 3 months from the onset of covid-19 symptoms 5. parent's/carer's/guardians consent to participate exclusion criteria: 1. recruit patients who have used antibiotics, systemic steroids, and immunosuppressants in the previous month. 2. patients with c1 esterase inhibitor deficiency, lymphocytopenia, thrombocytopenia, severe diseases involving heart, liver, or kidney, metabolic disease, or autoimmune disease.

Keywords: post-acute covid-19 syndromes (pacs) long covid human microbiome vitamin d
efficacy and tolerability of escitalopram and duloxetine in outpatients with major depressive disorder

Conditions: Major Depressive Disorder

Summary: the primary objective of this study was to compare the efficacy of escitalopram with that of duloxetine in outpatients with major depressive disorder (mdd) after 24 weeks of treatment. the study hypothesis was that there were clinically important differences between the two drugs in terms of efficacy and adverse event profiles.

depression is a common mental disorder that presents with depressed mood, loss of interest or pleasure, disturbed sleep or appetite, low energy, feelings of guilt or low self-worth, and poor concentration. the lifetime prevalence of major depressive disorder (mdd) in community samples is 10-25% for women and 5-12% for men. depression may become chronic or recurrent and lead to substantial impairments in an individual's ability to take care of his or her everyday responsibilities. at its worst, depression may lead to suicide. depression is recurrent in 75-80% of patients and becomes chronic in 15-20% of depressed patients. the selective serotonin reuptake inhibitors (ssris) have become the leading class of antidepressants throughout the world. the efficacy and safety of ssris in the treatment of depression has been demonstrated in several clinical trials. with respect to safety, the studies show an advantage for the ssris over the older antidepressants. if the prescribing physicians are to make a well-founded judgement in their choice of drug factors like efficacy, safety, quality of life, and health economics must be taken into consideration. the primary aim of this study is to compare the efficacy of escitalopram with that of the serotonin norepinephrine reuptake inhibitors (snris) duloxetine in the treatment of mdd.

Eligibility criteria:
inclusion criteria: * the patient suffers from a primary diagnosis of mdd according to dsm-iv-tr criteria (classification code 296.xx; current episode assessed using the mini) * the patient has a madrs total score \>=26 and a cgi-s score \>=4 at the baseline visit exclusion criteria: * any current psychiatric disorder other than mdd as defined in the dsm-iv tr * female patients of childbearing potential who are not using effective contraception * use of any psychoactive medication 2 weeks prior to screening and during the study other protocol-defined inclusion and exclusion criteria may apply.

Keywords: depressive disorder, major randomized controlled trials antidepressive agents
clinical trial of l. reuteri in urinary tract infections in non pregnant women

Conditions: Urinary Tract Infections

Summary: rct to evaluate the safety and efficacy of lactobacillus reuteri dsm 16666 \& lactobacillus reuteri dsm 17938 to significantly modify the frequency of clinical or bacteriological cure in women with non complicated acute cystitis who receive probiotics for 12 days compared with the frequency in women who receive placebo.

randomized, double blind, placebo controlled, pilot trial to evaluate the safety and efficacy of l. reuteri in non menopausal women with non complicated cystitis in terms of the frequency of clinical or bacteriological cure. secondary outcomes will be a) time to clinical/laboratory relapse in at least 70% of women with non complicated acute cystitis who receive probiotics for 12 days compared with the time in women who receive placebo; b) frequency of clinical/laboratory and bacteriologic relapse in women with non complicated acute cystitis who receive probiotics for 12 days compared with the frequency in women who receive placebo, at day 30 after treatment start and c) frequency of adverse related events in women with non complicated acute cystitis who receive probiotics for 12 days compared with the frequency in women who receive placebo. in the active product we will use 5\*10\^8 cfu of lactobacillus reuteri dsm 16666 \& lactobacillus reuteri dsm 17938 + cranberry extract. the control group will recibe cranberry extract. the products will be taken twice per day, morning and evening.

Eligibility criteria:
inclusion criteria: * non pregnant pre menopausal women * minimum age 18 years * uncomplicated cystitis diagnosed by urine dipstick testing (nitrates +, leukocytes esterase * and/or 105 cfu/ml or nitrates +, leukocytes esterase + and/or 102 -103 cfu/ml+ clinical symptoms) and an evaluation of the presence of typical related symptoms. in particular, frequency (frequent voiding of urine), urgency (the urge to void immediately), dysuria (painful voiding), and/or suprapubic pain. * verbal and written informed consent for participation in the study exclusion criteria: * acute cystitis symptoms for \>1week before the first visit * diabetes mellitus, * congenital urinary tract abnormality * lactating women * female who intend to become pregnant during the study or within 3 months after the completion of the study * vaginal discharge + fever (\>37.5oc) * diagnostic of sexually transmitted diseases * use of an indwelling catheter or an intermittent self-catheterisation program * presence of neurogenic bladder, or * use of any antibiotic 2 weeks before day 1 in the study.
effectiveness of neural therapy in patients with fibromiyalgia

Conditions: Fibromyalgia

Summary: neural therapy is a regulation therapy that tries to correct this underlying autonomic dysfunction. in neural therapy; local painful areas, trigger points and symptomatic segments are included in the injection using local anesthetics and the underlying disruptive areas are investigated and treated. the aim of this study was to investigate the efficacy of neural therapy in fibromyalgia syndrome which is thought to have a neuroendocrine dysregulation disorder.

fibromyalgia is a chronic disease characterized by widespread body pain, fatigue, sleep disturbance, and tenderness on palpation at trigger points in the musculoskeletal system. fibromyalgia prevalence is reported between 3% and 9%, and is three times more common in women than men. although pharmacological and non-pharmacological approaches play a role in the treatment of the disease, the interest in non-pharmacological therapies has recently increased. in several studies, it has been shown that almost every fibromyalgia patient has applied at least one alternative and complementary medicine method such as qigong, tai chi, yoga, mind body interventions, acupuncture, hydrotherapy, balneotherapy or phytotherapy. neural therapy is a regulation therapy that tries to correct this underlying autonomic dysfunction. in neural therapy; local painful areas, trigger points and symptomatic segments are included in the injection using local anesthetics and the underlying disruptive areas are investigated and treated. the aim of this study was to investigate the efficacy of neural therapy in fibromyalgia syndrome which is thought to have a neuroendocrine dysregulation disorder.

Eligibility criteria:
inclusion criteria: * subjects diagnosed according to the american college of rheumatology 2016 diagnostic criteria for fibromyalgia. exclusion criteria: * history of comorbid inflammatory rheumatic/ connective tissue diseases * history of cardiovascular or musculoskeletal problems that could prevent them to participate in an exercise program

Keywords: neural therapy physical theraphy lidocain injection